95,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
48 °P sammeln
  • Broschiertes Buch

This is the second edition of a well-received book that reflects the state of the art in cancer medical therapies and their side-effects, including immunotherapy and chemotherapeutic drugs. All chapters have been fully updated to include all the latest progress in drug discovery such as targeted therapies for each cancer type. From issues such as preservation of fertility to antiemetic therapy the book provides a very comprehensive overview of the field. The book includes a new chapter on immuno-oncology drugs. Organised by organ system, it lists the toxicity, side-effects and measures of…mehr

Produktbeschreibung
This is the second edition of a well-received book that reflects the state of the art in cancer medical therapies and their side-effects, including immunotherapy and chemotherapeutic drugs. All chapters have been fully updated to include all the latest progress in drug discovery such as targeted therapies for each cancer type. From issues such as preservation of fertility to antiemetic therapy the book provides a very comprehensive overview of the field. The book includes a new chapter on immuno-oncology drugs.
Organised by organ system, it lists the toxicity, side-effects and measures of prevention pertaining to each type of drug used in cancer therapy. The most dangerous side-effects are priority so as to alert the reader to their importance.
Designed for quick reference in the clinical setting this book is primarily aimed at established medical oncologists but will also appeal to junior doctors, trainees, pharmacistsand nurses.
Autorenporträt
Mario Dicato, Hematology-Oncology Service at Luxembourg Medical Center, Luxembourg, and Head of the Research Laboratory of the Luxembourg Foundation for Research on Cancer and Blood Disorders. M. Dicato trained at Lausanne University, completed his postgraduate training at the Universities of Geneva, Switzerland, Pittsburgh and Yale, USA. He did his fellowship (subspecialty training) in hematology at the Massachusetts General Hospital, Boston and was Clinical and Research Fellow in Medicine at Harvard University, Boston, USA.He has published more than 250 papers and numerous book chapters, and is an editorial board member of several scientific journals. Eric VanCutsem, MD, PhD, is professor at the University of Leuven and  head of the division of Digestive Oncology at the University Hospitals Leuven, Belgium. He trained at the University of Leuven and spent part of his training in Lausanne, Bristol, San Antonio and Rotterdam. He published more than 500 peer-reviewed articles. He is member of the Belgian Royal Academy of Medicine and president of the Belgian Foundation Against. He is/was a committee or board member of several international scientific organizations, including ESMO, ASCO, EORTC, UEG, ESDO, ENETS.